| 丁笑笑,丁新华,王雯雯,陈建霖,林佩佩,郭艳荣.R-CDOP方案治疗弥漫大B细胞淋巴瘤的效果及对免疫功能、预后影响[J].中国医药导报,2024,21(2):116-119 |
二维码（扫一下试试看！） |
| R-CDOP方案治疗弥漫大B细胞淋巴瘤的效果及对免疫功能、预后影响 |
| Efficacy of R-CDOP regimen in the treatment of diffuse large B-cell lymphoma and its influence on immune function and prognosis |
| 收稿日期：2023-03-17 |
| DOI：10.20047/j.issn1673-7210.2024.02.24 |
| 关键词: 多柔比星脂质体 弥漫大B细胞淋巴瘤 免疫功能 毒副作用 预后 |
| Key Words: |
| 基金项目:浙江省医药卫生计划项目（2020KY1053） |
|
| 摘要点击次数: 746 |
| 全文下载次数: 309 |
| 摘要:目的 探讨R-CDOP方案治疗弥漫大B细胞淋巴瘤的效果及对免疫功能、预后影响。 方法 选取2017年10月至2020年6月于浙江省台州市中心医院（台州学院附属医院）诊治且随访至2022年7月的52例弥漫大B细胞淋巴瘤患者作为研究对象，按照随机数字表法分为观察组（予以R-CDOP方案治疗）与对照组（予以R-CHOP方案治疗），各26例。比较两组有效率、免疫功能（CD3+、CD4+、CD8+）、毒副作用、2年生存率及生存时间。 结果 观察组客观有效率、完全缓解率高于对照组，差异有统计学意义（P＜0.05）。化疗后，两组CD3+、CD4+低于化疗前，且观察组高于对照组；两组CD8+高于化疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。观察组毒副作用总发生率低于对照组，差异有统计学意义（P＜0.05）。观察组2年生存率、生存时间高于对照组，差异有统计学意义（P＜0.05）。结论 R-CDOP方案治疗弥漫大B细胞淋巴瘤效果显著，有利于减轻对免疫功能的影响，且安全性高。 |
| Abstract:Objective To investigate the efficacy, immune function, and prognosis of R-CDOP in the treatment of diffuse large B-cell lymphoma. Methods Fifty-two patients with diffuse large B-cell lymphoma who were treated in Taizhou Central Hospital (Taizhou University Hospital) from October 2017 to June 2020 and followed up until July 2022 were selected as the study objects. According to random number table method, they were divided into observation group (treated with R-CDOP regimen) and control group (treated with R-CHOP regimen), with 26 cases each. Response rate, immune function (CD3+, CD4+, CD8+), toxicity, two-year survival rate and survival time of two groups were compared. Results The objective effective rate and complete remission rate of the observation group were higher than those of the control group, and the differences were statistically significant (P＜0.05). After chemotherapy, CD3+ and CD4+ in two groups were lower than before chemotherapy, and those of the observation group were higher than those of the control group; CD8+ in both groups was higher than before chemotherapy, and that of the observation group was lower than that of the control group and the differences were statistically significant (P＜0.05). The total incidence of side effects in the observation group was lower than that in the control group, and the difference was statistically significant (P＜0.05). The 2-year survival rate and survival time of the observation group were higher than those of the control group, and the differences were statistically significant (P＜0.05). Conclusion R-CDOP is effective in the treatment of diffuse large B-cell lymphoma, which is beneficial to reduce the influence on immune function and has high safety. |
| 查看全文 HTML 查看/发表评论 下载PDF阅读器 |
|
|
|
